Pharmamarketeer

Aethlon Hemopurifier cancer therapy receives US FDA breakthrough device designational

Aethlon Medical, Inc, a therapeutic technology company focused on unmet needs in global health, has received a “Breakthrough Device” designation from the US Food and Drug Administration (FDA) to support the advancement of the Aethlon Hemopurifier for the treatment of cancer. The Aethlon Hemopurifier is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and life-threatening viruses.

Medhc-fases-banner
Advertentie(s)